The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis
Status and phase
Conditions
Treatments
Details and patient eligibility
About
Emotionally labile, depressed participants with multiple sclerosis treated with escitalopram will have a greater reduction in emotional lability scores and in their psychological distress scores than those who are randomized to receive placebo.
Full description
Patients with multiple sclerosis who are experiencing mood lability and symptoms of depression will be randomized to receive either escitalopram 10mg/day or placebo tablets for a period of 6 weeks. It is hypothesized that patients receiving medication will experience a greater normalization of their emotional instability and a greater reduction in their depressive symptoms at the end of the six-week trial than those who are not receiving medication.
Sex
Ages
Volunteers
Inclusion criteria
- Clinical diagnosis of multiple sclerosis
- Having mild to moderate depressive symptoms, with or without emotional lability
- Experiencing psychological distress
Exclusion criteria
- Meeting DSM-IV diagnostic criteria for Major Depressive Disorder or another Axis 1 diagnosis
- Cognitive impairment
- The presence of an unstable medical illness that might preclude completion of the study -
Trial design
Primary purpose
Allocation
Interventional model
Masking
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal